SCHEMBL2269165

SCHEMBL2269165

COc1ccc(C(=O)Nc2cc(-c3ccccc3)ccc2C(=O)O)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.69
KMT2A Q03164 4/20 0.69
PKM P14618 1/20 0.69
NPSR1 Q6W5P4 1/20 0.69
HDAC2 Q92769 2/20 0.67
ADORA3 P0DMS8 1/20 0.64
PRSS12 P56730 2/20 0.63
ACLY P53396 2/20 0.63
DHODH Q02127 1/20 0.62
F10 P00742 1/20 0.61
MAPT P10636 2/20 0.61
ALDH1A1 P00352 2/20 0.60
KDM4E B2RXH2 1/20 0.60
HPGD P15428 1/20 0.60
KCNK2 O95069 1/20 0.59
KCNK10 P57789 1/20 0.59
TRPV1 Q8NER1 1/20 0.57
IGF2BP2 Q9Y6M1 1/20 0.57
NPC1 O15118 2/20 0.56
RAB9A P51151 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2275393 0.96 HDAC2 (0.73) MEN1KMT2APKMNPSR1HDAC2
SCHEMBL2274003 0.91 HDAC2 (0.66) MEN1KMT2APKMNPSR1HDAC2
SCHEMBL2270222 0.89 DHODH (0.77) MEN1KMT2APKMNPSR1HDAC2
SCHEMBL2271137 0.89 HDAC2 (0.74) MEN1KMT2APKMNPSR1HDAC2
SCHEMBL2270565 0.88 MEN1 (0.67) MEN1KMT2AHDAC2ACLYMAPT
SCHEMBL2269459 0.88 MEN1 (0.63) MEN1KMT2APKMNPSR1HDAC2
SCHEMBL1318785 0.86 PRSS12 (0.55) MEN1KMT2APKMNPSR1HDAC2
SCHEMBL2275453 0.86 ACLY (0.76) MEN1KMT2APKMHDAC2ACLY
SCHEMBL2269909 0.85 ACLY (0.67) MEN1KMT2APKMHDAC2ACLY
SCHEMBL2935687 0.85 MEN1 (0.69) MEN1KMT2APKMNPSR1F10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
CN-101094829-A Novel anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO LTD (JP) 2007-12-26 CN disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP26, MMP11 MEN1 3105/4885KMT2A 1669/4885PKM 2367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.